Quetiapine granules
AssigneeAstraZeneca AB
InventorDaniel Boyd Brown
Life of this patent
Estimating the term…
Abstract
Granule formulation of quetiapine and pharmaceutically acceptable salt thereof are described, as are their preparation and their use in treating diseases of the central nervous system such as psychotic disease conditions including schizophrenia.
Claims105
A granule formulation comprising 11-[4-[2-(2-hydroxyethoxy)etbyl]-l-piperazinyl]dibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof and a freely or very water-soluble binder, wherein the granules have a bulk density range of 0.15 g/cc to 0.60 g/cc and a tap density range of 0.20 g/cc to 0.70 g/cc and 80% of the granules are in the size range of 75 to 850 microns and wherein the granules have a moisture level in the range of 1.5% to 15%.
A granule formulation consisting of 11-[4-[2-(2-hydroxyethoxy)ethyl-1-piperazinyl]dibenzol[b,f][1.4]thiazepine or a pharmaceutically acceptable salt thereof, a freely or very water-soluble binder, and a sweetener wherein the granules have a bulk density range of 0.15 gee to 0.60 g/cc and a tap density range of 0.20 g/cc to 0.70 g/cc and 80% of the granules are in the size range of 75 to 850 microns and wherein the granules have a moisture level in the range of 1.5% to 15%.
Dependencies are inferred from the claim text.